Despite recent advances in the management of metastatic melanoma using targeted therapies, options for patients with tumors that are BRAF and NRAS wild type remain limited (Dummer et al., 2012). BRAF/NRAS wild type melanoma accounts for 13-26% of all melanoma cases (Hodis et al., 2012; Mar et al., 2013) and is generally characterized by a high C>T mutation burden, loss of function mutations and deletions of NF1, and activating mutations of KIT. Amplification of KIT, CCND1 and TERT are also observed in this disease (Hodis et al., 2012; Mar et al., 2013). Dacarbazine chemotherapy is the standard of care for patients with this molecular class of melanoma, but response rates in advanced disease are disappointing (Dummer et al., 2012; Tsao et al., 2004).This article is protected by copyright. All rights reserved.